Inactive Total Small Business Set-Aside (FAR 19.5)

The National Institutes of Health (NIH) and the Centers for Disease Control and Prevention (CDC) are soliciting proposals from small business concerns that possess the research and development (R&D) e... The National Institutes of Health (NIH) and the Centers for Disease Control and Prevention (CDC) are soliciting proposals from small business concerns that possess the research and development (R&D) expertise to conduct innovative research that will contribute toward NIH or CDC mission needs and Small Business Innovation Research (SBIR) program objectives. THE U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES (DHHS), THE NATIONAL INSTITUTES OF HEALTH (NIH), AND THE CENTERS FOR DISEASE CONTROL AND PREVENTION (CDC) SMALL BUSINESS INNOVATIVE RESEARCH (SBIR) PROGRAM SOLICITATION PHS-2022-1 is anticipated to be made available on or around July 28, 2021, through both SAM.gov and the NIH Small Business Innovation Research (SBIR)/Small Business Technology Transfer (STTR) funding web page at https://sbir.nih.gov/funding. This solicitation is anticipated to have a closing date of October 28, 2021 for receipt of proposals. The purposes of the SBIR program are to: (a) stimulate technological innovation; (b) strengthen the role of small business in meeting Federal research/research & development (R/R&D) needs; (c) foster and encourage participation by socially and economically disadvantaged small business concerns and women-owned business concerns; and (d) increase private sector commercialization of innovations derived from Federal R/R&D, thereby increasing competition, productivity and economic growth. For purposes of the SBIR program, a small business concern is any business concern that, on the date of award, (1) is organized for profit, with a place of business located in the United States, which operates primarily within the United States or which makes a significant contribution to the United States economy through payment of taxes or use of American products, materials or labor; (2) is in the legal form of an individual proprietorship, partnership, limited liability company, corporation, joint venture, association, trust or cooperative, except that where the form is a joint venture, there must be less than 50 percent participation by foreign business entities in the joint venture; (3) more than 50% directly owned and controlled by one or more individuals (who are citizens or permanent resident aliens of the United States), other business concerns (each of which is more than 50% directly owned and controlled by individuals who are citizens or permanent resident aliens of the United States), or any combination of these; OR more than 50% owned by multiple venture capital operating companies, hedge funds, private equity firms, or any combination of these. No single venture capital operating company, hedge fund, or private equity firm may own more than 50% of the concern; AND, (4) has, including its affiliates, no more than 500 employees.* * Note: This size standard is established by law for the SBIR program, regardless of the NAICS Code assigned. See 13 C.F.R. § 121.702. THE FOLLOWING RESEARCH TOPICS ARE ANTICIPATED TO BE INCLUDED IN SBIR CONTRACT SOLICITATION PHS-2022-1 NATIONAL INSTITUTES OF HEALTH (NIH) NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES (NCATS): Topic 022 - Technological Development and Validation of Remote Measures for Use in Clinical Trials in Individuals with Rare Diseases NATIONAL CANCER INSTITUTE (NCI): Topic 430 - Development of Senotherapeutic Agents for Cancer Treatment Topic 431 - Cancer Treatment Technologies for Low-Resource Settings Topic 432 - Synthetic Biology Gene Circuits for Cancer Therapy Topic 433 - Developing Unbiased Medical Technologies to Reduce Disparities in Cancer Outcomes Topic 434 - Ultra-Fast Dose Rate (FLASH) Radiation Detectors and Safety Systems Topic 435 - Devices to Treat Secondary Lymphedema Following Cancer Treatment Topic 436 - New Technologies to Analyze Extra-Chromosomal DNA in Cancer Topic 437 - 3D Spatial Omics for Molecular and Cellular Tumor Atlas Construction Topic 438 - Understanding Cancer Tumor Genomic Results: Technology Applications for Community Providers Topic 439 - Advanced Sample Processing Platforms for Downstream Single-Cell Multi-Omic Analysis Topic 440 - Cancer Prevention and Diagnosis Technologies for Low-Resource Settings Topic 441 - At-Home Screening for Hepatitis C Virus Topic 442 - Quantitative Biomarkers as Medical Device Development Tools for Cancer Topic 443 - Development of Computer-Aided Diagnosis Tools for Upper and Lower Gastrointestinal Tract Cancer Prevention Topic 444 - Evaluation Datasets as Medical Device Development Tools for Testing Cancer Technologies Topic 445 - Advanced Manufacturing to Speed Availability of Emerging Autologous Cell-based Therapies NATIONAL INSTITUTE ON AGING (NIA): Topic 004 - Improving CNS Gene Delivery Systems for AD/ADRD Therapy Development Topic 005 - Geroscience-based Chronic Wound Treatment Product Development Topic 006 - The Development of Mechanism-based Adult Stem Cell Treatments to Combat Aging Pathologies NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (NIAID): Topic 101 - Novel Platforms for Delivery and/or Expression of HIV Env Immunogens for HIV Vaccines Topic 102 - Genetically Engineered Mice for Pre-clinical Evaluation of HIV Vaccine Candidates Topic 103 - Development of Diagnostics to Differentiate HIV Infection from Vaccine Induced Seropositivity Topic 104 - Adjuvant Discovery for Vaccines and for Autoimmune and Allergic Diseases Topic 105 - Adjuvant Development for Vaccines and for Autoimmune and Allergic Diseases Topic 106 - Production of Adjuvants Mimics Topic 107 - Reagents for Immunologic Analysis of Non-mammalian and Underrepresented Mammalian Models Topic 108 - Development of Rapid POC Diagnostics for Treponema pallidum Topic 109 - Development of Monoclonal Antibody-mediated Interventions to Combat Malaria Topic 110 - Point of Care (POC) Diagnostics for Antimicrobial Resistant (AMR) Enteric Bacterial and Parasitic Pathogens Topic 111 - Data Science Tools for Infectious and Immune-mediated Disease Research Topic 112 - Digital Tools Against Misinformation about Infectious Disease Treatments and Vaccines CENTERS FOR DISEASE CONTROL AND PREVENTION (CDC) NATIONAL CENTER ON BIRTH DEFECTS AND DEVELOPMENTAL DISABILITIES (NCBDDD): Topic 020 - Open-Source and User-Friendly Record Linkage/De-duplication Tool NATIONAL CENTER FOR CHRONIC DISEASE PREVENTION AND HEALTH PROMOTION (NCCDPHP): Topic 044 - Algorithmic Database Food Product Tool to Align Food Service with Guidelines NATIONAL CENTER FOR EMERGING ZOONOTIC AND INFECTIOUS DISEASE (NCEZID): Topic 028 - Develop Rapid, Portable, Point-of-Care C. auris Diagnostic Topic 029 - Product to Inactivate and Stabilize Wastewater Samples for Shipping and Transport NATIONAL CENTER FOR HIV/AIDS, VIRAL HEPATITIS, STD, AND TB PREVENTION (NCHHSTP): Topic 052 - Electronic Health Record Algorithm to Identify Persons with HIV Not in Care Topic 053 - Simultaneous Detection of Molecular and Serological Markers via Next-Generation Sequencing NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES (NCIRD): Topic 035 - Nanoparticle-based Multi-Antigen Influenza Vaccine that Induces both Antibody and Cell-Mediated Immune Responses NOTE – SBIR / STTR GRANT OPPORTUNITIES SBIR and STTR grant opportunities are also available for investigator-initiated ideas. Companies are encouraged to review omnibus SBIR/STTR grant solicitations of the National Institutes of Health, Centers for Disease Control and Prevention and Food and Drug Administration posted on the NIH SBIR/STTR funding web page located at https://sbir.nih.gov/funding#omni-sbir. Standard due dates for SBIR/STTR grant applications are September 5th, January 5th, and April 5th. To understand better the differences between grants and contracts, see https://sbir.nih.gov/apply. For general information regarding the NIH/CDC SBIR Program, please refer to: Office of Extramural Programs, Office of Extramural Research National Institutes of Health Phone 301-435-2688 sbir@od.nih.gov

Inactive Total Small Business Set-Aside (FAR 19.5)

Synopsis: The National Institutes of Health (NIH) and the Centers for Disease Control and Prevention (CDC) are soliciting proposals from small business concerns that possess the research and developme... Synopsis: The National Institutes of Health (NIH) and the Centers for Disease Control and Prevention (CDC) are soliciting proposals from small business concerns that possess the research and development (R&D) expertise to conduct innovative research that will contribute toward NIH or CDC mission needs and Small Business Innovation Research (SBIR) program objectives. THE U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES (DHHS), THE NATIONAL INSTITUTES OF HEALTH (NIH), AND THE CENTERS FOR DISEASE CONTROL AND PREVENTION (CDC) SMALL BUSINESS INNOVATIVE RESEARCH (SBIR) PROGRAM SOLICITATION PHS-2022-1 is anticipated to be made available on or around July 28, 2021, through both SAM.gov and the NIH Small Business Innovation Research (SBIR)/Small Business Technology Transfer (STTR) funding web page at https://sbir.nih.gov/funding. This solicitation is anticipated to have a closing date of October 28, 2021 for receipt of proposals. The purposes of the SBIR program are to: (a) stimulate technological innovation; (b) strengthen the role of small business in meeting Federal research/research & development (R/R&D) needs; (c) foster and encourage participation by socially and economically disadvantaged small business concerns and women-owned business concerns; and (d) increase private sector commercialization of innovations derived from Federal R/R&D, thereby increasing competition, productivity and economic growth. For purposes of the SBIR program, a small business concern is any business concern that, on the date of award, (1) is organized for profit, with a place of business located in the United States, which operates primarily within the United States or which makes a significant contribution to the United States economy through payment of taxes or use of American products, materials or labor; (2) is in the legal form of an individual proprietorship, partnership, limited liability company, corporation, joint venture, association, trust or cooperative, except that where the form is a joint venture, there must be less than 50 percent participation by foreign business entities in the joint venture; (3) more than 50% directly owned and controlled by one or more individuals (who are citizens or permanent resident aliens of the United States), other business concerns (each of which is more than 50% directly owned and controlled by individuals who are citizens or permanent resident aliens of the United States), or any combination of these; OR more than 50% owned by multiple venture capital operating companies, hedge funds, private equity firms, or any combination of these. No single venture capital operating company, hedge fund, or private equity firm may own more than 50% of the concern; AND, (4) has, including its affiliates, no more than 500 employees.* * Note: This size standard is established by law for the SBIR program, regardless of the NAICS Code assigned. See 13 C.F.R. § 121.702. THE FOLLOWING RESEARCH TOPICS ARE ANTICIPATED TO BE INCLUDED IN SBIR CONTRACT SOLICITATION PHS-2022-1 NATIONAL INSTITUTES OF HEALTH (NIH) NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES (NCATS): Topic 022 - Technological Development and Validation of Remote Measures for Use in Clinical Trials in Individuals with Rare Diseases NATIONAL CANCER INSTITUTE (NCI): Topic 430 - Development of Senotherapeutic Agents for Cancer Treatment Topic 431 - Cancer Treatment Technologies for Low-Resource Settings Topic 432 - Synthetic Biology Gene Circuits for Cancer Therapy Topic 433 - Developing Unbiased Medical Technologies to Reduce Disparities in Cancer Outcomes Topic 434 - Ultra-Fast Dose Rate (FLASH) Radiation Detectors and Safety Systems Topic 435 - Devices to Treat Secondary Lymphedema Following Cancer Treatment Topic 436 - New Technologies to Analyze Extra-Chromosomal DNA in Cancer Topic 437 - 3D Spatial Omics for Molecular and Cellular Tumor Atlas Construction Topic 438 - Understanding Cancer Tumor Genomic Results: Technology Applications for Community Providers Topic 439 - Advanced Sample Processing Platforms for Downstream Single-Cell Multi-Omic Analysis Topic 440 - Cancer Prevention and Diagnosis Technologies for Low-Resource Settings Topic 441 - At-Home Screening for Hepatitis C Virus Topic 442 - Quantitative Biomarkers as Medical Device Development Tools for Cancer Topic 443 - Development of Computer-Aided Diagnosis Tools for Upper and Lower Gastrointestinal Tract Cancer Prevention Topic 444 - Evaluation Datasets as Medical Device Development Tools for Testing Cancer Technologies Topic 445 - Advanced Manufacturing to Speed Availability of Emerging Autologous Cell-based Therapies NATIONAL INSTITUTE ON AGING (NIA): Topic 004 - Improving CNS Gene Delivery Systems for AD/ADRD Therapy Development Topic 005 - Geroscience-based Chronic Wound Treatment Product Development Topic 006 - The Development of Mechanism-based Adult Stem Cell Treatments to Combat Aging Pathologies NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (NIAID): Topic 101 - Novel Platforms for Delivery and/or Expression of HIV Env Immunogens for HIV Vaccines Topic 102 - Genetically Engineered Mice for Pre-clinical Evaluation of HIV Vaccine Candidates Topic 103 - Development of Diagnostics to Differentiate HIV Infection from Vaccine Induced Seropositivity Topic 104 - Adjuvant Discovery for Vaccines and for Autoimmune and Allergic Diseases Topic 105 - Adjuvant Development for Vaccines and for Autoimmune and Allergic Diseases Topic 106 - Production of Adjuvants Mimics Topic 107 - Reagents for Immunologic Analysis of Non-mammalian and Underrepresented Mammalian Models Topic 108 - Development of Rapid POC Diagnostics for Treponema pallidum Topic 109 - Development of Monoclonal Antibody-mediated Interventions to Combat Malaria Topic 110 - Point of Care (POC) Diagnostics for Antimicrobial Resistant (AMR) Enteric Bacterial and Parasitic Pathogens Topic 111 - Data Science Tools for Infectious and Immune-mediated Disease Research Topic 112 - Digital Tools Against Misinformation about Infectious Disease Treatments and Vaccines CENTERS FOR DISEASE CONTROL AND PREVENTION (CDC) NATIONAL CENTER ON BIRTH DEFECTS AND DEVELOPMENTAL DISABILITIES (NCBDDD): Topic 020 - Open-Source and User-Friendly Record Linkage/De-duplication Tool NATIONAL CENTER FOR CHRONIC DISEASE PREVENTION AND HEALTH PROMOTION (NCCDPHP): Topic 044 - Algorithmic Database Food Product Tool to Align Food Service with Guidelines NATIONAL CENTER FOR EMERGING ZOONOTIC AND INFECTIOUS DISEASE (NCEZID): Topic 028 - Develop Rapid, Portable, Point-of-Care C. auris Diagnostic Topic 029 - Product to Inactivate and Stabilize Wastewater Samples for Shipping and Transport NATIONAL CENTER FOR HIV/AIDS, VIRAL HEPATITIS, STD, AND TB PREVENTION (NCHHSTP): Topic 052 - Electronic Health Record Algorithm to Identify Persons with HIV Not in Care Topic 053 - Simultaneous Detection of Molecular and Serological Markers via Next-Generation Sequencing NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES (NCIRD): Topic 035 - Nanoparticle-based Multi-Antigen Influenza Vaccine that Induces both Antibody and Cell-Mediated Immune Responses NOTE – SBIR / STTR GRANT OPPORTUNITIES SBIR and STTR grant opportunities are also available for investigator-initiated ideas. Companies are encouraged to review omnibus SBIR/STTR grant solicitations of the National Institutes of Health, Centers for Disease Control and Prevention and Food and Drug Administration posted on the NIH SBIR/STTR funding web page located at https://sbir.nih.gov/funding#omni-sbir. Standard due dates for SBIR/STTR grant applications are September 5th, January 5th, and April 5th. To understand better the differences between grants and contracts, see https://sbir.nih.gov/apply. For general information regarding the NIH/CDC SBIR Program, please refer to: Office of Extramural Programs, Office of Extramural Research National Institutes of Health Phone 301-435-2688 sbir@od.nih.gov